Antigen binding proteins

Patent metadata

Field	Value
Publication number	US-9624308-B2
Application number	US-201314440491-A
Country	US
Kind code	B2
Filing date	Nov 5, 2013
Priority date	Nov 5, 2012
Publication date	Apr 18, 2017
Grant date	Apr 18, 2017

Abstract

The present invention relates to novel antigen binding proteins, in particular monoclonal antibodies, capable of binding to the protein Axl as well as the amino and nucleic acid sequences coding for said proteins. From one aspect, the invention relates to novel antigen binding proteins, or antigen binding fragments, capable of binding to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding proteins as addressing products in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.

First claim

The invention claimed is:

1. An antigen binding protein that binds Axl and that is selected from the group consisting of:
a) an antibody comprising the three light chain CDRs comprising the sequences SEQ ID NOs. 1, 2 and 3; and the three heavy chain CDRs comprising the sequences SEQ ID NOs. 4 5 and 6;
b) an antibody comprising the three light chain CDRs comprising the sequences SEQ ID NOs. 36, 37 and 38; and the three heavy chain CDRs comprising the sequences SEQ ID NOs. 39, 40 and 41; and
c) an antibody comprising the three light chain CDRs comprising the sequences SEQ ID NOs. 64, 65 and 66; and the three heavy chain CDRs comprising the sequences SEQ ID NOs. 67, 68 and 69;
or an antigen binding fragment of the antibody of a), b), or c).

2. The antigen binding protein, or any antigen binding fragment thereof, according to claim 1 characterized in that it comprises the three light chain CDRs comprising the sequences SEQ ID NOs. 1, 2 and 3; and a heavy chain variable domain of sequence SEQ ID NO. 8, or any sequence exhibiting at least 80% identity with SEQ ID NO. 8.

3. The antigen binding protein, or any antigen binding fragment thereof, according to claim 1 , characterized in that it comprises a light chain variable domain of sequence SEQ ID NO. 7, or any sequence exhibiting at least 80% identity with SEQ ID NO. 7; and the three heavy chain CDRs comprising the sequences SEQ ID NOs. 4, 5 and 6.

4. The antigen binding protein, or any antigen binding fragment thereof, according to claim 1 characterized in that it comprises the three light chain CDRs comprising the sequences SEQ ID NOs. 36, 37 and 38; and a heavy chain variable domain of sequence SEQ ID NO. 43, or any sequence exhibiting at least 80% identity with SEQ ID NO. 43.

5. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , characterized in that it comprises a light chain variable domain of sequence SEQ ID NO. 42, or any sequence exhibiting at least 80% identity with SEQ ID NO. 42; and the three heavy chain CDRs comprising the sequences SEQ ID NOs. 39, 40 and 41.

6. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , characterized in that it comprises the three light chain CDRs comprising the sequences SEQ ID NOs. 64, 65 and 66; and a heavy chain variable domain of sequence SEQ ID NO. 71, or any sequence exhibiting at least 80% identity with SEQ ID NO. 71.

7. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , characterized in that it comprises a light chain variable domain of sequence SEQ ID NO. 70, or any sequence exhibiting at least 80% identity with SEQ ID NO. 70; and the three heavy chain CDRs comprising the sequences SEQ ID NOs. 67, 68 and 69.

8. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , characterized in that it comprises a light chain variable domain of sequence SEQ ID NO. 7 or any sequence exhibiting at least 80% identity with SEQ ID NO. 7; and a heavy chain variable domain of sequence SEQ ID NO. 8 or any sequence exhibiting at least 80% identity with SEQ ID NO. 8.

9. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , characterized in that it comprises a light chain variable domain of sequence SEQ ID NO. 42, or any sequence exhibiting at least 80% identity with SEQ ID NO. 42 and a heavy chain variable domain of sequence SEQ ID NO. 43, or any sequence exhibiting at least 80% identity with SEQ ID NO. 43.

10. The antigen binding protein, or an antigen binding fragment thereof, according to claim 1 , characterized in that it comprises a light chain variable domain of sequence SEQ ID NO. 70, or any sequence exhibiting at least 80% identity with SEQ ID NO. 70 and a heavy chain variable domain of sequence SEQ ID NO. 71, or any sequence exhibiting at least 80% identity with SEQ ID NO. 71.

11. The antigen binding protein according to claim 1 , wherein the antigen binding protein is selected from the group consisting of:
a) the monoclonal antibody 110D7 produced by the hybridoma l-3959deposited at the CNCM, Institut Pasteur, France, on 2 Apr. 2008, or an antigen binding fragment thereof;
b) the monoclonal antibody 1003A2 produced by the hybridoma l-4499deposited at the CNCM, Institut Pasteur, France, on 28 Jul. 2011, or an antigen binding fragment thereof; and
c) the monoclonal antibody 1024G11 produced by the hybridoma l-4501deposited at the CNCM, Institut Pasteur, France, on 28 Jul. 2011, or an antigen binding fragment thereof.

12. A murine hybridoma selected from the group consisting of:
a) the murine hybridoma l-3959 deposited at the CNCM, Institut Pasteur, France, on 2 Apr. 2008;
b) the murine hybridoma l-4499 deposited at the CNCM, Institut Pasteur, France, on 28 Jul. 2011; and
c) the murine hybridoma l-4501 deposited at the CNCM, Institut Pasteur, France, on 28 Jul. 2011.

13. An immunoconjugate comprising the antigen binding protein, or an antigen binding fragment thereof, according to claim 1 conjugated to a cytotoxic agent.

14. Pharmaceutical composition comprising the immunoconjugate of claim 13 and at least an excipient and/or a pharmaceutical acceptable vehicle.

Assignees

• Pf Medicament

Inventors

• Beau-Larvor Charlotte
• Goetsch Liliane
• Boute Nicolas

Classifications

• C07K2317/77

  Internalization into the cell · CPC title

• C07K16/30

  from tumour cells · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K47/6849

  the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title

• A61K47/6825

  Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin · CPC title